{
  "main_header": {
    "sid": 10038997,
    "name": "Saroja Pharma In",
    "stock_name": "Saroja Pharma In",
    "full_name": "Saroja Pharma Industries India Ltd",
    "name_url": "stocks-analysis/saroja-pharma-in",
    "exchange": 1,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "39.40",
    "chg": -1.8,
    "chgp": "-4.37%",
    "dir": -1,
    "prev_price": "41.20",
    "mcapval": "17.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": "",
    "symbol": "SAROJA",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE0PCL01011",
    "curr_date": "Dec 05",
    "curr_time": "",
    "bse_nse_vol": 3200,
    "exc_status": "Active",
    "traded_date": "Dec 05, 2025",
    "traded_date_str": "2025 12 05",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/saroja-pharma-in-10038997-1&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "How has been the historical performance of Saroja Pharma In?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-saroja-pharma-in-3699805",
        "imagepath": "",
        "date": "2025-11-13 23:51:10",
        "description": "Answer:\nThe historical performance of Saroja Pharma In shows fluctuations in key financial metrics over the past four years.\n\nBreakdown:\nSaroja Pharma In's net sales increased from 40.67 Cr in Mar'24 to 53.73 Cr in Mar'25, while total operating income also rose to 53.92 Cr from 40.67 Cr. However, the raw material cost saw a significant increase to 48.28 Cr in Mar'25 from 32.17 Cr in Mar'24. Total expenditure, excluding depreciation, increased to 50.94 Cr in Mar'25 from 38.12 Cr in Mar'24. Operating profit (PBDIT) rose to 2.98 Cr in Mar'25, up from 2.74 Cr in Mar'24, indicating improved operational efficiency despite rising costs. Profit before tax increased to 1.45 Cr in Mar'25 from 1.21 Cr in Mar'24, while profit after tax also grew to 1.03 Cr from 0.88 Cr. The earnings per share (EPS) rose to 2.56 in Mar'25 from 2.19 in Mar'24. On the balance sheet, total assets increased to 39.55 Cr in Mar'25 from 26.56 ..."
      },
      {
        "title": "Why is Saroja Pharma In falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-saroja-pharma-in-fallingrising-3691422",
        "imagepath": "",
        "date": "2025-11-12 00:10:32",
        "description": "As of 11-Nov, Saroja Pharma Industries India Ltd is experiencing a decline in its stock price, currently at 41.25, which reflects a decrease of 1.9 or 4.4%. The stock has underperformed its sector by 4.27% today and is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages. Additionally, there has been a significant drop in investor participation, with delivery volume falling by 66.67% compared to the 5-day average. Over the past week, the stock has decreased by 4.40%, and it has also shown a substantial decline of 31.25% year-to-date, indicating ongoing challenges for the company.\n\nIn the broader market context, while Saroja Pharma's stock has fallen significantly, the benchmark Sensex has shown a slight increase of 0.38% over the past week and a gain of 8.67% year-to-date. This stark contrast highlights the stock's underperformance relative to the market. The overall negative sentim..."
      },
      {
        "title": "Why is Saroja Pharma In falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-saroja-pharma-in-fallingrising-3636367",
        "imagepath": "",
        "date": "2025-10-20 23:11:58",
        "description": "As of 20-Oct, Saroja Pharma Industries India Ltd is experiencing a decline in its stock price, currently at 43.60, which reflects a decrease of 2.0 or 4.39%. The stock has underperformed its sector by 5.07% today, and while it is higher than the 100-day moving average, it is lower than the 5-day, 20-day, 50-day, and 200-day moving averages. Over the past week, the stock has dropped by 7.43%, and year-to-date, it has decreased by 27.33%. Notably, there has been a significant rise in investor participation, with delivery volume increasing by 233.33% against the 5-day average, indicating some interest despite the overall negative performance. Unfortunately, there is no available information regarding positive or negative factors that could further explain the stock's recent movement.\n\nIn the broader market context, Saroja Pharma's short-term performance has been notably weaker compared to the benchmark Sensex,..."
      },
      {
        "title": "Is Saroja Pharma In overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-saroja-pharma-in-overvalued-or-undervalued-3597238",
        "imagepath": "",
        "date": "2025-10-07 08:06:10",
        "description": "As of 6 October 2025, Saroja Pharma's valuation grade has moved from fair to expensive, indicating a shift towards overvaluation. The company is currently deemed overvalued based on its key financial ratios, including a PE ratio of 17.45, an EV to EBITDA of 9.09, and a PEG ratio of 1.02. In comparison to its peers, Sun Pharma has a significantly higher PE ratio of 34.56, while Cipla, which is rated attractive, has a PE ratio of 22.72, further highlighting Saroja Pharma's relative overvaluation.\n\nGiven these metrics and the recent performance, Saroja Pharma appears overvalued in the current market context. The company's stock has underperformed the Sensex over the past year, with a return of -22.06% compared to the Sensex's modest gain of 0.25%. This underperformance, coupled with the elevated valuation ratios, reinforces the conclusion that Saroja Pharma is not a compelling investment at its current price o..."
      },
      {
        "title": "Is Saroja Pharma In overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-saroja-pharma-in-overvalued-or-undervalued-3592451",
        "imagepath": "",
        "date": "2025-10-06 08:05:14",
        "description": "As of 3 October 2025, Saroja Pharma's valuation grade has moved from expensive to fair. The company is currently fairly valued, with a PE ratio of 16.71, a Price to Book Value of 1.10, and an EV to EBITDA ratio of 8.84. In comparison to its peers, Sun Pharma has a significantly higher PE ratio of 34.04, indicating it is expensive, while Dr. Reddy's Labs, which is considered attractive, has a PE ratio of 18.34.\n\nSaroja Pharma's financial metrics suggest it is positioned well within its industry, especially with a PEG ratio of 0.98, indicating potential growth relative to its earnings. However, the company's stock has underperformed against the Sensex, with a year-to-date return of -28.67% compared to the Sensex's 5.28%. This performance may reflect market sentiment rather than the underlying valuation, reinforcing the view that Saroja Pharma is fairly valued at its current price of 42.80...."
      },
      {
        "title": "Why is Saroja Pharma In falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-saroja-pharma-in-fallingrising-3568672",
        "imagepath": "",
        "date": "2025-09-24 23:40:49",
        "description": "As of 24-Sep, Saroja Pharma Industries India Ltd's stock price is flat at 46.00, showing no change (0.00%). The stock has underperformed in the short term, with a 1-week return of -2.23% compared to the Sensex's -1.08%. Over the past month, the stock has declined by 17.12%, while the Sensex has gained 0.75%. Additionally, the stock's year-to-date performance is down 23.33%, contrasting with the Sensex's increase of 5.97%. Today's price summary indicates that the stock has outperformed its sector by 0.45%, but it is experiencing a decline in investor participation, with delivery volume dropping by 37.5% against the 5-day average. The stock is trading above its 50-day, 100-day, and 200-day moving averages, but below its 5-day and 20-day moving averages, suggesting mixed technical signals.\n\nIn the broader market context, Saroja Pharma's recent performance highlights a significant divergence from the benchmark ..."
      },
      {
        "title": "Why is Saroja Pharma In falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-saroja-pharma-in-fallingrising-3562639",
        "imagepath": "",
        "date": "2025-09-23 23:50:29",
        "description": "As of 23-Sep, Saroja Pharma Industries India Ltd's stock price is flat at 46.00, with no change (0.00%). The stock has underperformed in the short term, with a 1-week return of -2.23% and a 1-month return of -17.12%. Today's price summary indicates that the stock outperformed its sector by 0.35%, but it is currently above the 50-day, 100-day, and 200-day moving averages while being below the 5-day and 20-day moving averages. Additionally, there has been a significant decline in investor participation, as the delivery volume on 22 September fell by 37.5% compared to the 5-day average, which may indicate waning interest. Unfortunately, there is no information available regarding positive or negative factors that could influence the stock's movement.\n\nIn the broader market context, Saroja Pharma's recent performance contrasts sharply with the benchmark Sensex, which has shown a slight decline of only -0.28% ov..."
      },
      {
        "title": "Why is Saroja Pharma In falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-saroja-pharma-in-fallingrising-3555871",
        "imagepath": "",
        "date": "2025-09-22 23:40:26",
        "description": "As of 22-Sep, Saroja Pharma Industries India Ltd is experiencing a price increase, with its current price at 46.00, reflecting a change of 0.85 or 1.88% upward. Despite this positive movement today, the stock has shown a decline of 2.23% over the past week and a significant drop of 17.12% over the past month. The stock is currently trading above its 50-day, 100-day, and 200-day moving averages, but below its 5-day and 20-day moving averages. Additionally, there has been a notable decrease in investor participation, with delivery volume falling by 50% compared to the 5-day average, which may indicate waning interest among investors.\n\nIn the broader market context, while Saroja Pharma's stock has outperformed its sector by 2.96% today, it has underperformed the benchmark Sensex over the past week and month, which have seen gains of 0.53% and 1.34%, respectively. Year-to-date, Saroja Pharma's stock has decline..."
      },
      {
        "title": "Why is Saroja Pharma In falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-saroja-pharma-in-fallingrising-3540436",
        "imagepath": "",
        "date": "2025-09-19 23:36:05",
        "description": "As of 19-Sep, Saroja Pharma Industries India Ltd is experiencing a decline in its stock price, currently at 45.15, reflecting a decrease of 2.3 or 4.85%. The stock has underperformed its sector by 5.12% today, and while it is trading higher than the 50-day and 100-day moving averages, it is below the 5-day, 20-day, and 200-day moving averages. Over the past week, the stock has decreased by 4.04%, and it has seen a significant drop of 19.59% over the past month. Despite a rise in investor participation, with delivery volume increasing by 11.11% against the 5-day average, the overall performance remains negative, with no positive or negative dashboard data available to provide further insights.\n\nIn the broader market context, the stock's recent performance contrasts sharply with the benchmark Sensex, which has gained 0.85% over the past week and 1.39% over the past month. Year-to-date, Saroja Pharma's stock h..."
      }
    ],
    "total": 63,
    "sid": "10038997",
    "stock_news_url": "https://www.marketsmojo.com/news/saroja-pharma-industries-india-10038997"
  },
  "announcements": "",
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

How has been the historical performance of Saroja Pharma In?

2025-11-13 23:51:10

Answer: The historical performance of Saroja Pharma In shows fluctuations in key financial metrics over the past four years. Breakdown: Saroja Pharma In's net sales increased from 40.67 Cr in Mar'24 to 53.73 Cr in Mar'25, while total operating income also rose to 53.92 Cr from 40.67 Cr. However, the raw material cost saw a significant increase to 48.28 Cr in Mar'25 from 32.17 Cr in Mar'24. Total expenditure, excluding depreciation, increased to 50.94 Cr in Mar'25 from 38.12 Cr in Mar'24. Operating profit (PBDIT) rose to 2.98 Cr in Mar'25, up from 2.74 Cr in Mar'24, indicating improved operational efficiency despite rising costs. Profit before tax increased to 1.45 Cr in Mar'25 from 1.21 Cr in Mar'24, while profit after tax also grew to 1.03 Cr from 0.88 Cr. The earnings per share (EPS) rose to 2.56 in Mar'25 from 2.19 in Mar'24. On the balance sheet, total assets increased to 39.55 Cr in Mar'25 from 26.56 ...

Read More

Why is Saroja Pharma In falling/rising?

2025-11-12 00:10:32

As of 11-Nov, Saroja Pharma Industries India Ltd is experiencing a decline in its stock price, currently at 41.25, which reflects a decrease of 1.9 or 4.4%. The stock has underperformed its sector by 4.27% today and is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages. Additionally, there has been a significant drop in investor participation, with delivery volume falling by 66.67% compared to the 5-day average. Over the past week, the stock has decreased by 4.40%, and it has also shown a substantial decline of 31.25% year-to-date, indicating ongoing challenges for the company. In the broader market context, while Saroja Pharma's stock has fallen significantly, the benchmark Sensex has shown a slight increase of 0.38% over the past week and a gain of 8.67% year-to-date. This stark contrast highlights the stock's underperformance relative to the market. The overall negative sentim...

Read More

Why is Saroja Pharma In falling/rising?

2025-10-20 23:11:58

As of 20-Oct, Saroja Pharma Industries India Ltd is experiencing a decline in its stock price, currently at 43.60, which reflects a decrease of 2.0 or 4.39%. The stock has underperformed its sector by 5.07% today, and while it is higher than the 100-day moving average, it is lower than the 5-day, 20-day, 50-day, and 200-day moving averages. Over the past week, the stock has dropped by 7.43%, and year-to-date, it has decreased by 27.33%. Notably, there has been a significant rise in investor participation, with delivery volume increasing by 233.33% against the 5-day average, indicating some interest despite the overall negative performance. Unfortunately, there is no available information regarding positive or negative factors that could further explain the stock's recent movement. In the broader market context, Saroja Pharma's short-term performance has been notably weaker compared to the benchmark Sensex,...

Read More

Is Saroja Pharma In overvalued or undervalued?

2025-10-07 08:06:10

As of 6 October 2025, Saroja Pharma's valuation grade has moved from fair to expensive, indicating a shift towards overvaluation. The company is currently deemed overvalued based on its key financial ratios, including a PE ratio of 17.45, an EV to EBITDA of 9.09, and a PEG ratio of 1.02. In comparison to its peers, Sun Pharma has a significantly higher PE ratio of 34.56, while Cipla, which is rated attractive, has a PE ratio of 22.72, further highlighting Saroja Pharma's relative overvaluation. Given these metrics and the recent performance, Saroja Pharma appears overvalued in the current market context. The company's stock has underperformed the Sensex over the past year, with a return of -22.06% compared to the Sensex's modest gain of 0.25%. This underperformance, coupled with the elevated valuation ratios, reinforces the conclusion that Saroja Pharma is not a compelling investment at its current price o...

Read More

Is Saroja Pharma In overvalued or undervalued?

2025-10-06 08:05:14

As of 3 October 2025, Saroja Pharma's valuation grade has moved from expensive to fair. The company is currently fairly valued, with a PE ratio of 16.71, a Price to Book Value of 1.10, and an EV to EBITDA ratio of 8.84. In comparison to its peers, Sun Pharma has a significantly higher PE ratio of 34.04, indicating it is expensive, while Dr. Reddy's Labs, which is considered attractive, has a PE ratio of 18.34. Saroja Pharma's financial metrics suggest it is positioned well within its industry, especially with a PEG ratio of 0.98, indicating potential growth relative to its earnings. However, the company's stock has underperformed against the Sensex, with a year-to-date return of -28.67% compared to the Sensex's 5.28%. This performance may reflect market sentiment rather than the underlying valuation, reinforcing the view that Saroja Pharma is fairly valued at its current price of 42.80....

Read More

Why is Saroja Pharma In falling/rising?

2025-09-24 23:40:49

As of 24-Sep, Saroja Pharma Industries India Ltd's stock price is flat at 46.00, showing no change (0.00%). The stock has underperformed in the short term, with a 1-week return of -2.23% compared to the Sensex's -1.08%. Over the past month, the stock has declined by 17.12%, while the Sensex has gained 0.75%. Additionally, the stock's year-to-date performance is down 23.33%, contrasting with the Sensex's increase of 5.97%. Today's price summary indicates that the stock has outperformed its sector by 0.45%, but it is experiencing a decline in investor participation, with delivery volume dropping by 37.5% against the 5-day average. The stock is trading above its 50-day, 100-day, and 200-day moving averages, but below its 5-day and 20-day moving averages, suggesting mixed technical signals. In the broader market context, Saroja Pharma's recent performance highlights a significant divergence from the benchmark ...

Read More

Why is Saroja Pharma In falling/rising?

2025-09-23 23:50:29

As of 23-Sep, Saroja Pharma Industries India Ltd's stock price is flat at 46.00, with no change (0.00%). The stock has underperformed in the short term, with a 1-week return of -2.23% and a 1-month return of -17.12%. Today's price summary indicates that the stock outperformed its sector by 0.35%, but it is currently above the 50-day, 100-day, and 200-day moving averages while being below the 5-day and 20-day moving averages. Additionally, there has been a significant decline in investor participation, as the delivery volume on 22 September fell by 37.5% compared to the 5-day average, which may indicate waning interest. Unfortunately, there is no information available regarding positive or negative factors that could influence the stock's movement. In the broader market context, Saroja Pharma's recent performance contrasts sharply with the benchmark Sensex, which has shown a slight decline of only -0.28% ov...

Read More

Why is Saroja Pharma In falling/rising?

2025-09-22 23:40:26

As of 22-Sep, Saroja Pharma Industries India Ltd is experiencing a price increase, with its current price at 46.00, reflecting a change of 0.85 or 1.88% upward. Despite this positive movement today, the stock has shown a decline of 2.23% over the past week and a significant drop of 17.12% over the past month. The stock is currently trading above its 50-day, 100-day, and 200-day moving averages, but below its 5-day and 20-day moving averages. Additionally, there has been a notable decrease in investor participation, with delivery volume falling by 50% compared to the 5-day average, which may indicate waning interest among investors. In the broader market context, while Saroja Pharma's stock has outperformed its sector by 2.96% today, it has underperformed the benchmark Sensex over the past week and month, which have seen gains of 0.53% and 1.34%, respectively. Year-to-date, Saroja Pharma's stock has decline...

Read More

Why is Saroja Pharma In falling/rising?

2025-09-19 23:36:05

As of 19-Sep, Saroja Pharma Industries India Ltd is experiencing a decline in its stock price, currently at 45.15, reflecting a decrease of 2.3 or 4.85%. The stock has underperformed its sector by 5.12% today, and while it is trading higher than the 50-day and 100-day moving averages, it is below the 5-day, 20-day, and 200-day moving averages. Over the past week, the stock has decreased by 4.04%, and it has seen a significant drop of 19.59% over the past month. Despite a rise in investor participation, with delivery volume increasing by 11.11% against the 5-day average, the overall performance remains negative, with no positive or negative dashboard data available to provide further insights. In the broader market context, the stock's recent performance contrasts sharply with the benchmark Sensex, which has gained 0.85% over the past week and 1.39% over the past month. Year-to-date, Saroja Pharma's stock h...

Read More

View All News